QIVIGY LogoQIVIGY

Contact a Rep

PHASE 3 STUDY DESIGN: The efficacy of QIVIGY® was evaluated in an open-label, prospective clinical study in adult patients with primary humoral immunodeficiency. A total of 47 patients received intravenous infusions of QIVIGY at a dose of 266 mg/kg to 826 mg/kg on a 4-week (n=39) or a 3-week (n=8) infusion cycle for 12 months. There are no comparative head-to-head trials with QIVIGY.1,2

NOW AVAILABLE

EXPECTATIONS ELEVATED

In a 12-month study, QIVIGY achieved quality patient outcomes1,2: 

0

ACUTE SERIOUS BACTERIAL INFECTIONS
per person-year
(99% confidence limit: 0.10; n=47)1,2

Bacteria

0 DAYS OF HOSPITALIZATION
due to infection per person-year1

3% OF THE YEAR ON ANTIBIOTICS1*

93% OF PATIENTS WERE SATISFIED WITH QIVIGY2†

EXPECT MORE WITH QIVIGY.

Start QIVIGYSee dosing and ordering information

*The median (min, max) duration of antibiotic treatment of any kind of infection was 10 days (1, 334). A total of 36 (76.6%) patients used at least 1 course of concomitant antibiotic therapy for treatment of infections. Eleven patients (23.4%) did not require antibiotic treatment.2

†A study-specific patient satisfaction questionnaire was an exploratory endpoint in the trial and collected from all 47 treated patients at Week 24. Questionnaire results also showed 68% of patients were satisfied with their previous IVIG therapy.2

References: 1. QIVIGY [prescribing information]. Kedrion Biopharma Inc.; 2025. 2. Data on file. REF-01262. Kedrion Biopharma Inc.; 2024.

Important Safety Information
Back to Top

INDICATIONS AND USAGE

QIVIGY® (immune globulin intravenous, human-kthm) is a 10% immune globulin (Ig) liquid indicated for the treatment of adults with primary humoral immunodeficiency.

Important safety information

WARNING: THROMBOSIS, RENAL DYSFUNCTION, and ACUTE RENAL FAILURE

See full prescribing information for complete boxed warning.

  • Thrombosis may occur with immune globulin products, including QIVIGY.
  • Renal dysfunction, acute renal failure, osmotic nephrosis may occur with immune globulin intravenous (IGIV) products in predisposed patients. Such events require immediate medical intervention, if not recognized or managed appropriately, may result in persistent or significant disability or incapacity or lead to fatal outcome.
  • For patients at risk of thrombosis, renal dysfunction or failure, administer QIVIGY at the minimum dose available and the minimum infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

CONTRAINDICATIONS

QIVIGY is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin and in IgA deficient patients with antibodies against IgA and history of hypersensitivity.

WARNINGS AND PRECAUTIONS

Severe hypersensitivity reactions, including anaphylaxis, may occur. In case of hypersensitivity, discontinue QIVIGY infusion and manage as appropriate.

Hyperproteinemia, hyperviscosity, and hyponatremia may occur in patients receiving IGIV treatment, including QIVIGY.

Aseptic meningitis syndrome may occur in patients receiving IGIV treatment, especially with high doses or rapid infusion.

Hemolysis can develop subsequent to IGIV treatment. Monitor patients for hemolysis.

Transfusion-related acute lung injury: Monitor patients for pulmonary adverse reactions.

Transmissible infectious agents: QIVIGY is made from human plasma and may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Interference with laboratory tests: After infusion of Ig, transitory rise of passively transferred antibodies may yield positive serological results, with potential for misleading interpretation.

ADVERSE REACTIONS

The most common adverse reactions occurring in ≥5% of patients treated were headache, fatigue, infusion-related reaction, Coombs direct test positive, nausea, sinusitis, dizziness, and diarrhea.

To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma Inc. at 1-855-3KDRION (1-855-353-7466) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for complete prescribing details, including Boxed Warning.